4594 — BrightPath Biotherapeutics Co Income Statement
0.000.00%
Last trade - 00:00
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
Standards: | JAS | JAS | JAS | JAS | JAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 156 | 11.3 | 2.5 | 15.4 | 5.28 |
Cost of Revenue | |||||
Gross Profit | 85.1 | 6.83 | 1.36 | 12.1 | 3.38 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 2,024 | 1,874 | 1,714 | 1,491 | 1,482 |
Operating Profit | -1,868 | -1,863 | -1,711 | -1,476 | -1,477 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -1,881 | -1,860 | -1,717 | -1,482 | -1,484 |
Provision for Income Taxes | |||||
Net Income After Taxes | -1,884 | -1,858 | -1,720 | -1,484 | -1,486 |
Net Income Before Extraordinary Items | |||||
Net Income | -1,884 | -1,858 | -1,720 | -1,484 | -1,486 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -1,884 | -1,858 | -1,720 | -1,484 | -1,486 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -41.8 | -43.6 | -36.4 | -28.5 | -24.8 |
Dividends per Share |